FDA slaps down Novartis' blockbuster pitch for canakinumab — so what went wrong?
In a major setback, Novartis used its quarterly earnings report to flag an FDA slapdown on their application to market canakinumab for cardio risk reduction …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
